n°109

October 2010

Issue Contents
Editorial

Free  Making a difference

p.196
Grassroots healthcare professionals

Marketing Authorisations

Tolvaptan (SIADH) (New drug)

p.197-200
Evidence of efficacy is missing

Tolvaptan: no tangible efficacy in heart failure either

p.199

Tolvaptan: consolation prize

p.200
Editors’ opinion

Ofatumumab (chronic lymphocytic leukaemia) (New drug)

p.201-203
A last resort

Parecoxib and fatal skin reactions (Labelling change)

p.203
Unacceptable approval

Free  Ketoprofen gels (Regulatory problems)

p.204-205
Unfortunately back on French market

INN common stems : -mab

p.205

INN common stems : -ermin

p.205

Sildenafil (mild pulmonary arterial hypertension) (New indication)

p.206
Unjustified risks, no tangible benefit

Free  Benfluorex (Market withdrawal)

p.206
EU marketing authorisation finally withdrawn

Catumaxomab (malignant ascites) (New drug)

p.207-209
Unjustified marketing authorisation

Adverse Effects

Elderly dementia patients and neuroleptics: excess mortality

p.210-212
Both conventional and atypical neuroleptics

High-dose methotrexate during pregnancy: risk of malformations

p.212-213
Strict precautions needed

Methotrexate during the first trimester of pregnancy

p.213

Drug-induced acneiform rash

p.214-216
Reversible

Tocilizumab: intestinal perforations

p.216
In rheumatoid arthritis patients

Ketoprofen gel: severe photosensitisation

p.216
Beware topical NSAIDs

Injectable promethazine: gangrene

p.216-217
Do not inject promethazine

Injectable paracetamol in children: fatal confusion between milligrams and millilitres

p.217
Paracetamol injection rarely justified

Lenalidomide: myocardial infarction

p.217
Thalidomide safer

Olanzapine: sudden cardiac death, urinary incontinence

p.217
Typical of neuroleptics

Entacapone: prostate cancer?

p.217
To be confirmed

Anaesthetic ointments: fatal overdose in adults

p.218
Beware cosmetic procedures

Calcium dobesilate: neutropenia

p.218
A detailed report

Phloroglucinol: serious allergic reactions

p.218
Best to avoid

Reviews

Chemotherapy of metastatic colorectal cancer

p.219-224
Fluorouracil (+ folinic acid), oxaliplatin, irinotecan, combinations depending on the situation
Main chemotherapy protocols evaluated in metastatic colorectal cancer

Fluorouracil, oxaliplatin and irinotecan, alone or in combination

p.221
Prescrire's advice

Ambulatory blood pressure measurement

p.224-227
Few data on cardiovascular prevention

Appropriate use of 24-hour ambulatory blood pressure measurement

p.227
Prescrire's advice

Cardiac arrest in the out-of-hospital setting

p.228-229
When to halt resuscitation

Outlook

Reporting of errors by healthcare professionals

p.230-234
A safety culture

Free  The French medical sales charter: ineffective

p.235
Safer to avoid sales reps

Free  Medical research centres: deceptive press releases

p.236
A healthy dose of skepticism is needed

Letters - Hypertension in adults without diabetes or complications: what is the target blood pressure?

p.237-238
Weak evidence for 140/90 mmHg

Free  Prescrire files a complaint against the European Medicines Agency (EMA)

p.240

Masthead

Free  Masthead

p.194

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe